Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritis
Molecular Therapy · 2024-12 · 32 (12) · 4497-4513
DOI: 10.1016/j.ymthe.2024.09.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024-12. Verfasst von Liqing Ke und 16 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Angiopoietin-Like Protein 4. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Special Project for Research and Development in Key areas of Guangdong Province, Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers.
Abstract (Originalsprache)
Despite recent advances, rheumatoid arthritis (RA) patients remain refractory to therapy. Dysregulated overproduction of angiopoietin-like protein 4 (ANGPTL4) is thought to contribute to the disease development. ANGPTL4 was initially identified as a regulator of lipid metabolism, which is hydrolyzed to N-terminal and C-terminal (cANGPTL4) fragments in vivo. cANGPTL4 is involved in several non-lipid-related processes, including angiogenesis and inflammation. This study revealed that the level of ANGPTL4 was markedly elevated in the sera and synovial tissues from patients with RA versus controls. The administration of a neutralizing antibody against cANGPTL4 (anti-cANGPTL4 Ab) resulted in the inhibition of inflammatory processes and bone loss in animal models of collagen-induced arthritis and adjuvant-induced arthritis (AIA). Transcriptomic and proteomic profiling of synovial tissues from an AIA model indicated that the anti-cANGPTL4 Ab inhibited fibroblast-like synoviocyte (FLS) immigration and inflammatory-induced osteoclastogenesis. Mechanistically, the anti-cANGPTL4 Ab has been shown to inhibit TNF-α-induced inflammatory cascades in RA-FLS through the sirtuin 1/nuclear factor-κB signaling pathway. Moreover, the anti-cANGPTL4 Ab was found to block FLS invasion- and immigration-induced osteoclast activation. Collectively, these findings identify ANGPTL4 as a prospective biomarker for the diagnosis of RA, and targeting cANGPTL4 should represent a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.
- Department of Bone Joint and Musculoskeletal Tumor, Shenzhen Second People's Hospital (The First Affiliated Hospital of Shenzhen University), Shenzhen, Guangdong 518035, China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong 518055, China.
- Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing 100053, China.
- Department of Pathology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China.
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China; Shenzhen University of Advanced Technology, Shenzhen, Guangdong 518060, China; School of Biomedical Sciences, Un…
Förderung
- National Natural Science Foundation of China
- Special Project for Research and Development in Key areas of Guangdong Province
- Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers
- National Key Research and Development Program of China
Zitieren
APA
Ke, L., He, Q., Qu, J., Wang, X., Li, K., Gong, X., Li, L., Xu, J., Yu, Q., Yu, H., Lin, X., Li, J., Tan, N. S., Sun, W., Li, L., Zhang, P., & Cheng, W. (2024). Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritis. Molecular Therapy, 32(12), 4497-4513. https://doi.org/10.1016/j.ymthe.2024.09.031
Vancouver
Ke L, He Q, Qu J, Wang X, Li K, Gong X, et al. Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritis. Molecular Therapy. 2024;32(12):4497-4513. doi:10.1016/j.ymthe.2024.09.031
BibTeX
@article{Ke2024,
author = {Ke, Liqing and He, Qifei and Qu, Jing and Wang, Xiyue and Li, Kaibo and Gong, Xun and Li, Lan and Xu, Jiake and Yu, Qiuliyang and Yu, Hao and Lin, Xuefei and Li, Jian and Tan, Nguan Soon and Sun, Wei and Li, Liang and Zhang, Peng and Cheng, Wenxiang},
title = {Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritis},
journal = {Molecular Therapy},
year = {2024},
volume = {32},
number = {12},
pages = {4497--4513},
doi = {10.1016/j.ymthe.2024.09.031}
}
EUVIMED